Accessibility Menu
Moleculin Biotech logo

Moleculin Biotech(NASDAQ) MBRX

Current Price$2.17
Market Cap$11.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-89%
1 Month-25%
Moleculin Biotech last closing stock price
MetricPriceDate
Last closeUSD 2.152026-07-21
Moleculin Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.87%USD 2.262026-07-14
1 month-25.35%USD 2.882026-06-18
3 month-14%USD 2.502026-04-22
Year to date-35.05%USD 3.312025-12-31
1 year-89.28%USD 20.062025-07-21
3 year-99.14%USD 250.612023-07-21
5 year-99.83%USD 1,245.002021-07-22
Since inception-99.99%USD 18,000.002016-06-02

Moleculin Biotech Financials at a Glance

Market Cap

$11.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.33M

EPS (TTM)

-$28.04

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$2.17

Volume

9

Open

$2.17

Previous Close

$2.15

Daily Range

$2.17 - $2.17

52-Week Range

$1.79 - $19.83

Estimated Earnings Date

Aug 11, 2026

MBRX News

Foolcom-Featured.png

Moleculin Biotech Misses Fiscal Q2 EPS

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Moleculin Biotech

Moleculin develops new medicines for hard-to-treat cancers and viruses. Its drugs aim to help patients with few treatment options. The company focuses on therapies for leukemia, brain tumors, and rare cancers.

Lab Bench to Bedside: Moleculin’s Main Offerings

  • Annamycin (0% revenue): Chemotherapy drug in trials for leukemia and lung-metastasized cancers; targets patients with resistant disease.
  • WP1066 Portfolio (0% revenue): Immune system modulators for brain tumors and pancreatic cancer; designed for both adults and children.
  • WP1220 (0% revenue): Topical treatment for cutaneous T-cell lymphoma, a rare skin cancer.
  • WP1122 Portfolio (0% revenue): Drugs that block tumor and virus energy supply; tested for brain cancer and COVID-19.

Growth Spurts and Strategic Moves

  • Formed research partnerships with MD Anderson and WPD Pharmaceuticals since 2015.
  • Expanded clinical trials to Europe and the US from 2018 onward.
  • Launched pivotal Phase 3 trial for Annamycin in 2025.
  • Entered planned pancreatic cancer trials with Atlantic Health System in 2026.
  • Secured new patents and regulatory designations through 2025 to extend exclusivity.

What Makes Moleculin Stand Out

Moleculin’s drugs are designed to overcome resistance and side effects seen with older treatments. The company outsources manufacturing and relies on research partnerships to advance its pipeline. Its therapies target rare and difficult cancers, aiming to fill gaps left by larger pharmaceutical firms.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; all activities are pre-commercial.
  • Net loss was $33.6 million in 2025, up 28.9% from 2024.
  • Cash used in operations was $22.7 million in 2025, down 5% from 2024.
  • Cash and equivalents were $8.9 million as of December 31, 2025.
  • Seventeen full-time employees manage all research and operations.

Bottom Line

Moleculin remains focused on developing new cancer drugs, with no sales yet. Its future depends on clinical trial progress and securing more funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

Walter V. Klemp, CPA

Website

www.moleculin.com

Headquarters

Houston, TX 77007, US

MBRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3114.17%

Return on Capital

-163.38%

Return on Assets

-129.83%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

-5.82%

Stock Overview

Market Cap

$11.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.34M

Volume

9

Avg. Volume

513.13K

Financials (TTM)

Gross Profit

-$37.00K

Operating Income

-$27.03M

EBITDA

-$30.26M

Operating Cash Flow

-$24.28M

Capital Expenditure

$0.00

Free Cash Flow

-$24.28M

Cash & ST Invst.

$10.32M

Total Debt

$326.00K

Moleculin Biotech Performance Analysis

Moleculin Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Moleculin Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Moleculin Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -380.5171.6%
20232023-12-31USD -376.71-1.0%
20242024-12-31USD -189.14-49.8%
20252025-12-31USD -28.42-85.0%
Moleculin Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.2%
Q32025-09-30-38.4%
Q42025-12-31128.4%
Q12026-03-31-173.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$8.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$674.89K

N/A

Employees

17

N/A

Net Income

-$12.85M

-99.6%

EBITDA

-$12.84M

-100.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.32M

+33.7%

Total Debt

$326.00K

-27.6%

Accounts Receivable

$9.00K

+50.0%

Inventory

$0.00

N/A

Long Term Debt

$185.00K

-43.3%

Short Term Debt

$141.00K

+13.7%

Return on Assets

-1.30%

N/A

Return on Invested Capital

-1.76%

N/A

Free Cash Flow

-$6.11M

-33.9%

Operating Cash Flow

-$6.11M

-33.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ICUSeaStar Medical Holding Corporation
$3.86+0.02%
LNAILunai Bioworks Inc.
$2.73-1.27%
BLRXBioLineRx Ltd.
$2.97+1.54%
AIMDAinos, Inc.
$1.61+3.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$9.37+5.37%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.25-0.00%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.28+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.51+0.00%

Questions About MBRX

What is the current price of Moleculin Biotech?

Moleculin Biotech is trading at $2.17 per share.

What is the 52-week range for Moleculin Biotech?

Over the past 52 weeks, Moleculin Biotech has traded between $1.79 and $19.83.

How much debt does Moleculin Biotech have?

As of the most recent reporting period, Moleculin Biotech reported total debt of $326.00K.

How much cash does Moleculin Biotech have on hand?

Moleculin Biotech reported $10.32M in cash and cash equivalents in its most recent financial results.

What is Moleculin Biotech’s dividend yield?

Moleculin Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services